Facet Biotech confirms hostile bid from Biogen Idec

7 September 2009

Facet Biotech Corp has confirmed that it is in receipt of fellow USA-based Biogen Idec's letter dated September 4, 2009 offering $14.50 per share for all of the outstanding shares of Facet, valuing the firm at around $356 million. Biogen and Facet have worked together in the development of potential treatments for multiple sclerosis and solid tumors since 2005. The companies have been jointly developing the drugs daclizumab for MS and volociximab for cancer.

The latter's shares shot up 75% to $15.75 after being halted briefly. So far this year, Facet's shares have traded as low as $6 and as high as $11, and the Biogen offer is a 64% premium to its previous day's closing price.

Last month, Facet announced a collaboration with another US firm, Trubion Pharmaceuticals, to develop the leukemia drug TRU-016, which Biogen believes reduces the value of Facet, as apparently do Facet's investors, as evidenced by the 22% reduction in the firm's stock price since announcing the Trubion collaboration."

Facet's board of directors, in consultation with its financial and legal advisors, previously rejected Biogen Idec's all-cash offer of $15 per share as not in the best interests of stockholders. Facet's board says it will respond promptly to Biogen Idec's more recent proposal and the company urges stockholders to await a further response from Facet before making any decisions.

Urging Facet to agree to its offer, Biogen chief executive, James Mullen,  said: "We believe this transaction will enable the important multiple sclerosis and solid tumor clinical programs that we have been working on in collaboration for nearly four years to have the best chance of reaching the market and improving patients' lives."

Meanwhile, the law firm of Wolf Haldenstein Adler Freeman & Herz has said it is investigating possible breaches of fiduciary duty by Facet's  board arising out of its rejection of proposals by Biogen to acquire the company at a huge premium.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology